
    
      This is a double-blind, randomized, parallel controlled, multicenter, clinical trial.
      Subjects inclusion by randomization after passing the screening, continuous administration
      the test drug (Taurolite) or control drug (Ursofalk) treatment for 24 weeks. Compare the
      safety and efficacy of Taurolite vs Ursofalk.

      At the end of the double-blind periodï¼Œenroll 100 subjects from both two group randomly ,for a
      consecutive treatment use TUDCA up to 24 weeks. Further evaluate the efficacy and safety of
      tauroursodeoxycholic acid (TUDCA) in the treatment of adult primary biliary cirrhosis (PBC)
      for a long time up to one year. Also evaluate the regimen's efficacy and safety that udca
      take placed by TUDCA in the treatment of adult primary biliary cirrhosis (PBC) for the
      patients who use udca treatment for 24 weeks.
    
  